Comparison of 22Mhz and 18Mhz High-frequency Probes for the Ultrasound Study of Temporal Arteries in Patients Suspected of Having Giant Cell Arteritis (ECHORTON)

Comparison of 2 Probes Frequencies in the Diagnosis of Giant Cell Arteritis

Evaluation of the structural features of temporal arteritis using two frequencies probes: 18 and 22Mhz.

Study Overview

• Status: Completed
• Conditions: Giant Cell Arteritis

Detailed Description

Comparison of the results obtained by using 2 different frequencies probes in the diagnosis of giant cell arteritis

• Study Type: Observational
• Enrollment (Actual): 80

Contacts and Locations

Study Locations

• France
  • Brest, France, 29609
    • CHRU de Brest

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

patients with suspicion of giant cell arteritis

Description

Inclusion Criteria:

• sedimentation rate> 50 mm/h or recent unusual headache or unusual fever, recent visual trouble or jaw claudication, or induration temporal arteritis

Exclusion Criteria:

• previous diagnosis of giant cell arteritis and relapse of the giant cell arteritis and opposition to participate

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
halo sign of temporal arteritis	hypoechogenicity of the wall artery	inclusion
compression sign of of temporal arteritis	persistent of increased inflammatory arteries wall	inclusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
halo sign of carotid arteritis	hypoechogenicity of the wall artery	inclusion
halo sign of subclavian arteritis	hypoechogenicity of the wall artery	inclusion
halo sign of axillary arteritis	hypoechogenicity of the wall artery	inclusion
other structural abnormalities in unilateral B mode	stenosis, occlusion	inclusion
other structural abnormalities in bilateral B mode	stenosis, occlusion	inclusion

Collaborators and Investigators

• Sponsor: University Hospital, Brest

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 17, 2019
• Primary Completion (ACTUAL): August 24, 2020
• Study Completion (ACTUAL): August 24, 2020

Study Registration Dates

• First Submitted: December 17, 2019
• First Submitted That Met QC Criteria: December 17, 2019
• First Posted (ACTUAL): December 19, 2019

Study Record Updates

• Last Update Posted (ACTUAL): August 24, 2021
• Last Update Submitted That Met QC Criteria: August 23, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: giant cell arteritis; ultrasound,
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Skin Diseases; Immune System Diseases; Autoimmune Diseases of the Nervous System; Autoimmune Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Muscular Diseases; Vasculitis; Skin Diseases, Vascular; Vasculitis, Central Nervous System; Polymyalgia Rheumatica; Giant Cell Arteritis; Arteritis
• Other Study ID Numbers: ECHORTON (29BRC19.0275)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All collected data that underlie results in a publication
• IPD Sharing Time Frame: Data will be available beginning 18 month and ending five years following the end of study
• IPD Sharing Access Criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No